{"organizations": [], "uuid": "930317da6105d5599865df916931fe9a2535551f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180216.html", "section_title": "Archive News &amp; Video for Friday, 16 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-oncolys-biopharma-invests-in-us-bi/brief-oncolys-biopharma-invests-in-us-biotech-venture-specialized-in-development-of-novel-oncolytic-adenovirus-idUSL4N1Q61KO", "country": "US", "domain_rank": 408, "title": "BRIEF-Oncolys BioPharma invests in US Biotech Venture Specialized in Development of Novel Oncolytic Adenovirus", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-16T17:36:00.000+02:00", "replies_count": 0, "uuid": "930317da6105d5599865df916931fe9a2535551f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-oncolys-biopharma-invests-in-us-bi/brief-oncolys-biopharma-invests-in-us-biotech-venture-specialized-in-development-of-novel-oncolytic-adenovirus-idUSL4N1Q61KO", "ord_in_thread": 0, "title": "BRIEF-Oncolys BioPharma invests in US Biotech Venture Specialized in Development of Novel Oncolytic Adenovirus", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "oncolys biopharma inc", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "unleash immuno oncolytics, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 16 (Reuters) - Oncolys BioPharma Inc\n* Says it will enter into an investment and share transfer agreement with Unleash Immuno Oncolytics, Inc., a biotech venture specialized in development of novel oncolytic adenovirus\n* Says it agrees to purchase $3 million convertible bonds issued by Unleash with the expected voting rights ratio of approximately 27 percent, when fully converted\n* Says it also agrees to purchase 294,118 ordinary shares of Precision Virologics held by Unleash for $330,000, which will increase Oncolysâ€™ voting rights ratio of Precision to 23 percent, approximately\nSource text in Japanese: goo.gl/y23PMq\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/y23PMq"], "published": "2018-02-16T17:36:00.000+02:00", "crawled": "2018-02-17T14:43:23.000+02:00", "highlightTitle": ""}